Triple attack on liver cancer: blocking blood flow plus immune boost shows promise
NCT ID NCT07658833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-involved tumors and good liver function. Researchers will measure overall survival, tumor shrinkage, and side effects to find the best combination and identify which patients benefit most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib, sorafenib, apatinib, bevacizumab, pembrolizumab, carfilzomib, sintilimab, teprotumumab
What this could lead to
If successful, this combination approach could offer a new way to control advanced liver cancer and extend survival for patients who cannot have surgery.
What could go wrong
This is a single-center study with 120 participants, so results may not apply broadly. Combining multiple treatments also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiayan Ni
RECRUITINGGuangzhou, None Selected, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••